CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for GT Biopharma Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

GT Biopharma Inc
505 MONTGOMERY STREET, 10TH FLOOR
Phone: (310) 551-4020p:310 551-4020 SAN FRANCISCO, CA  94111  United States Ticker: GTBPGTBP
Business Summary
GT Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of immuno-oncology therapeutic products based on its proprietary Tri-specific Killer Engager (TriKE) natural killer (NK) cell engager platform. Its TriKE platform is designed to harness and enhance the cancer-killing abilities of a patient’s immune system’s natural killer cells. Its product candidate pipeline includes GTB-3550, GTB-3650, GTB-5550, GTB-7550, GTB-6550, GTB-1050, and other product candidates. GTB-3550 is a TriKE comprised of two single-chain variable fragments (scFv) composed of the variable regions of the heavy and light chains of anti-CD16 and anti-CD33 antibodies and a modified form of IL-15. GTB-3650 is a TriKE which targets CD33 on the surface of myeloid leukemias. The Company also has a worldwide license agreement with the University of Minnesota to further develop and commercialize therapies using TriKE technology.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202412/31/2024YesYes--Yes

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Executive Chairman of the Board, Interim Chief Executive Officer MichaelBreen 61 3/2/2022 1/13/2021
Independent Vice Chairman of the Board Bruce J.Wendel 70 11/11/2020 11/11/2020
Chief Financial Officer Alan L.Urban 55 6/3/2024 6/9/2022
Independent Director Charles J.Casamento 78 5/1/2023 5/1/2023
Independent Director RajeshShrotriya 79 1/13/2021 1/13/2021

Business Names
Business Name
Georgetown Translational Pharmaceuticals, Inc.
GTBP
OXIS
Oxis Biotech, Inc.
OXISD

General Information
Number of Employees: 1 (As of 12/31/2024)
Outstanding Shares: 2,536,397 (As of 2/28/2025)
Shareholders: 28
Stock Exchange: NASD
Federal Tax Id: 941620407
Fax Number: (302) 655-5049
Email Address: christiw@oxis.com


Copyright © 2025 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Tuesday, April 8, 2025